Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%

Positive Trial Results:
Immuneering's Phase 2a trial for IMM-1-104, a therapy for pancreatic cancer, showed a 43% overall response rate (ORR) and an 86% disease control rate (DCR) when combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients13.

Tumor Reduction:
The combination of IMM-1-104 with modified FOLFIRINOX resulted in target lesion shrinkage in all evaluable patients, including a 100% reduction in one patient13.

Monotherapy Efficacy:
IMM-1-104 monotherapy in second-line pancreatic cancer demonstrated a 67% reduction in target lesions, supporting its development in first-line combinations13.

Tolerability Profile:
IMM-1-104 showed a favorable tolerability profile, with no Grade 3/4 adverse events in the monotherapy arm, suggesting potential for broader combination strategies and longer treatment durations13.

Stock Surge:
Immuneering's stock price surged 55% following the release of these promising trial results24.

Future Plans:
The company plans to expand the Phase 2a trial with additional combination arms and has received Fast Track designation from the FDA for the treatment of first- and second-line pancreatic cancer, as well as for unresectable or metastatic NRAS-mutant melanoma23.

Sources:

1. https://www.stocktitan.net/news/IMRX/immuneering-announces-positive-data-update-from-three-pancreatic-qz0ax76ko02f.html

2. https://www.investing.com/news/stock-market-news/immuneering-stock-soars-on-promising-pancreatic-cancer-trial-results-93CH-3800059

3. https://ir.immuneering.com/news-releases/news-release-details/immuneering-announces-positive-data-update-three-pancreatic

4. https://c.firstwordpharma.com/firstwordgroup/assets/images/stocksurge.jpg?sa=X&ved=2ahUKEwi26eCd2-iKAxU3mokEHVddLqsQB16BAgDEAI